Cargando…

Targeting cholesterol homeostasis in lung diseases

Macrophages are critical to organ structure and function in health and disease. To determine mechanisms by which granulocyte/macrophage-colony stimulating factor (GM-CSF) signaling normally maintains surfactant homeostasis and how its disruption causes pulmonary alveolar proteinosis (PAP), we evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Sallese, Anthony, Suzuki, Takuji, McCarthy, Cormac, Bridges, James, Filuta, Alyssa, Arumugam, Paritha, Shima, Kenjiro, Ma, Yan, Wessendarp, Matthew, Black, Diane, Chalk, Claudia, Carey, Brenna, Trapnell, Bruce C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579240/
https://www.ncbi.nlm.nih.gov/pubmed/28860566
http://dx.doi.org/10.1038/s41598-017-10879-w
_version_ 1783260669118775296
author Sallese, Anthony
Suzuki, Takuji
McCarthy, Cormac
Bridges, James
Filuta, Alyssa
Arumugam, Paritha
Shima, Kenjiro
Ma, Yan
Wessendarp, Matthew
Black, Diane
Chalk, Claudia
Carey, Brenna
Trapnell, Bruce C.
author_facet Sallese, Anthony
Suzuki, Takuji
McCarthy, Cormac
Bridges, James
Filuta, Alyssa
Arumugam, Paritha
Shima, Kenjiro
Ma, Yan
Wessendarp, Matthew
Black, Diane
Chalk, Claudia
Carey, Brenna
Trapnell, Bruce C.
author_sort Sallese, Anthony
collection PubMed
description Macrophages are critical to organ structure and function in health and disease. To determine mechanisms by which granulocyte/macrophage-colony stimulating factor (GM-CSF) signaling normally maintains surfactant homeostasis and how its disruption causes pulmonary alveolar proteinosis (PAP), we evaluated lipid composition in alveolar macrophages and lung surfactant, macrophage-mediated surfactant clearance kinetics/dynamics, and cholesterol-targeted pharmacotherapy of PAP in vitro and in vivo. Without GM-CSF signaling, surfactant-exposed macrophages massively accumulated cholesterol ester-rich lipid-droplets and surfactant had an increased proportion of cholesterol. GM-CSF regulated cholesterol clearance in macrophages in constitutive, dose-dependent, and reversible fashion but did not affect phospholipid clearance. PPARγ-agonist therapy increased cholesterol clearance in macrophages and reduced disease severity in PAP mice. Results demonstrate that GM-CSF is required for cholesterol clearance in macrophages, identify reduced cholesterol clearance as the primary macrophage defect driving PAP pathogenesis, and support the feasibility of translating pioglitazone as a novel pharmacotherapy of PAP.
format Online
Article
Text
id pubmed-5579240
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-55792402017-09-06 Targeting cholesterol homeostasis in lung diseases Sallese, Anthony Suzuki, Takuji McCarthy, Cormac Bridges, James Filuta, Alyssa Arumugam, Paritha Shima, Kenjiro Ma, Yan Wessendarp, Matthew Black, Diane Chalk, Claudia Carey, Brenna Trapnell, Bruce C. Sci Rep Article Macrophages are critical to organ structure and function in health and disease. To determine mechanisms by which granulocyte/macrophage-colony stimulating factor (GM-CSF) signaling normally maintains surfactant homeostasis and how its disruption causes pulmonary alveolar proteinosis (PAP), we evaluated lipid composition in alveolar macrophages and lung surfactant, macrophage-mediated surfactant clearance kinetics/dynamics, and cholesterol-targeted pharmacotherapy of PAP in vitro and in vivo. Without GM-CSF signaling, surfactant-exposed macrophages massively accumulated cholesterol ester-rich lipid-droplets and surfactant had an increased proportion of cholesterol. GM-CSF regulated cholesterol clearance in macrophages in constitutive, dose-dependent, and reversible fashion but did not affect phospholipid clearance. PPARγ-agonist therapy increased cholesterol clearance in macrophages and reduced disease severity in PAP mice. Results demonstrate that GM-CSF is required for cholesterol clearance in macrophages, identify reduced cholesterol clearance as the primary macrophage defect driving PAP pathogenesis, and support the feasibility of translating pioglitazone as a novel pharmacotherapy of PAP. Nature Publishing Group UK 2017-08-31 /pmc/articles/PMC5579240/ /pubmed/28860566 http://dx.doi.org/10.1038/s41598-017-10879-w Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Sallese, Anthony
Suzuki, Takuji
McCarthy, Cormac
Bridges, James
Filuta, Alyssa
Arumugam, Paritha
Shima, Kenjiro
Ma, Yan
Wessendarp, Matthew
Black, Diane
Chalk, Claudia
Carey, Brenna
Trapnell, Bruce C.
Targeting cholesterol homeostasis in lung diseases
title Targeting cholesterol homeostasis in lung diseases
title_full Targeting cholesterol homeostasis in lung diseases
title_fullStr Targeting cholesterol homeostasis in lung diseases
title_full_unstemmed Targeting cholesterol homeostasis in lung diseases
title_short Targeting cholesterol homeostasis in lung diseases
title_sort targeting cholesterol homeostasis in lung diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579240/
https://www.ncbi.nlm.nih.gov/pubmed/28860566
http://dx.doi.org/10.1038/s41598-017-10879-w
work_keys_str_mv AT salleseanthony targetingcholesterolhomeostasisinlungdiseases
AT suzukitakuji targetingcholesterolhomeostasisinlungdiseases
AT mccarthycormac targetingcholesterolhomeostasisinlungdiseases
AT bridgesjames targetingcholesterolhomeostasisinlungdiseases
AT filutaalyssa targetingcholesterolhomeostasisinlungdiseases
AT arumugamparitha targetingcholesterolhomeostasisinlungdiseases
AT shimakenjiro targetingcholesterolhomeostasisinlungdiseases
AT mayan targetingcholesterolhomeostasisinlungdiseases
AT wessendarpmatthew targetingcholesterolhomeostasisinlungdiseases
AT blackdiane targetingcholesterolhomeostasisinlungdiseases
AT chalkclaudia targetingcholesterolhomeostasisinlungdiseases
AT careybrenna targetingcholesterolhomeostasisinlungdiseases
AT trapnellbrucec targetingcholesterolhomeostasisinlungdiseases